Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status

FDA

On Tuesday, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Ionis Pharmaceuticals Inc.’s (NASDAQ:IONS) ION582 for Angelman syndrome (AS), a rare neurological disorder.

This designation follows promising results from the Phase 1/2 HALOS study, which showed significant clinical improvements in communication, cognition, and motor function, along with favorable safety data.